Tech Company Financing Transactions
Sentien Biotechnologies Funding Round
Sentien Biotechnologies, based in Lexington, secured investment from Boehringer Ingelheim Venture Fund and Portage Venture Partners.
Transaction Overview
Company Name
Announced On
8/11/2015
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Boehringer Ingelheim Venture Fund (Martin Heidecker)
Portage Venture Partners (Greg Bailey)
Proceeds Purpose
Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel�, a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
99 Hayden Ave. Building E 140
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Sentien has developed proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Richard Ganz
Chief Executive Officer
Brian Miller
Co-Founder
Biju Parekkadan
Browse more venture capital transactions:
Prev: 8/11/2015: Abiquo venture capital transaction
Next: 8/11/2015: Nantero venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs